Katherine Fermanich is a pharmacist who is specialized in Oncology in Madison, Wisconsin. Patients can reach her at 600 Highland Ave, Madison or contact her on 608-263-6400. Active license number of Katherine Fermanich is 21463-40 for Oncology in Wisconsin. Katherine Fermanich is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Katherine Fermanich speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Katherine Fermanich
Specialization:
Oncology
Credentials:
PHARMD
Gender:
Female
Location:
600 Highland Ave, Madison, Wisconsin, 53792-0001
Phone:
608-263-6400
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Katherine Fermanich are as mentioned below.
NPI Number:
1487461802
NPI Enumeration Date:
18 Dec, 2024
NPI Last Update On:
18 Dec, 2024
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Katherine Fermanich are as mentioned below.
Specialization
License Number
State
Status
Oncology
21463-40
Wisconsin
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
1731 Morgan Station Ct, Oconomowoc, Wisconsin
Zip:
53066-9328
Phone Number:
--
Fax Number:
--
Patients can reach Katherine Fermanich at 600 Highland Ave, Madison, Wisconsin or can call on phone at 608-263-6400.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 13 October, 2025.